Incyte Corporation (INCY)
🔔 Watch stock
Incyte earned the largest profit in its history in 2025: $1,286.7 million on revenue of $5,141.2 million. That is exactly why the stock looks inexpensive. The annual report filed February 10, 2026, also explains why the market hesitates: four of every five revenue dollars ride on a single active ingredient, and its U.S. patent protection runs out in 2028 — Incyte wrote that sentence itself. From the middle of 2026, that is roughly eight quarters away. Not investment advice — just the question of who pays the bills after 2028.
Appears in These Scanners
This stock currently matches 20 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Quality & Screener
AI Rating
Uses AIIncyte nennt im Geschäftsbericht 2025 „computational and AI-guided drug discovery“ als Teil der eigenen Forschungsplattform und kündigt im Quartalsbericht zum 31.03.2026 an, den KI-Einsatz auszuweiten — KI ist damit Werkzeug, aber keine eigene Umsatzquelle.
View the full file — quotes, sources, reviewed filings
„These include target identification and validation, high-throughput screening, medicinal chemistry, protein sciences and technology, computational and AI-guided drug discovery, structural biology, pharmacology, translational sciences, drug metabolism and pharmacokinetics, bioanalysis, and toxicology assessment."
Dazu gehören Zielstruktur-Identifizierung und -Validierung, Hochdurchsatz-Screening, medizinische Chemie, Proteinwissenschaften und -technologie, computergestützte und KI-geleitete Wirkstoffsuche, Strukturbiologie, Pharmakologie, translationale Wissenschaften, Arzneimittelstoffwechsel und Pharmakokinetik, Bioanalytik sowie Toxikologiebewertung.
„The use of artificial intelligence is increasing in the biopharmaceutical industry for research, marketing, manufacturing and commercialization purposes, and we anticipate increasing our use of technology that incorporates artificial intelligence in the future."
Der Einsatz künstlicher Intelligenz nimmt in der biopharmazeutischen Branche für Forschung, Marketing, Herstellung und Vermarktung zu, und wir gehen davon aus, unseren Einsatz von Technologie mit künstlicher Intelligenz künftig auszuweiten.
Filings Reviewed: 10-Q 2026-04-28 · 10-K 2026-02-10 · 10-Q 2025-10-28 · 10-Q 2025-07-29 · 10-Q 2025-04-29 · 10-K 2025-02-10
Rated on July 26, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.02 | 14.60 | 1,179 | 16.30 | 17.10 | 381 | 364 |
| 2025: Q1 | 0.80 | 7.00 | 1,053 | 19.50 | 15.00 | 266 | 263 |
| 2025: Q2 | 2.04 | – | 1,216 | 16.50 | 33.30 | 45 | 26 |
| 2025: Q3 | 2.11 | 287.40 | 1,366 | 20.00 | 31.10 | 559 | 545 |
| 2025: Q4 | 1.46 | 43.40 | 1,507 | 27.80 | 19.90 | 543 | 521 |
| 2026: Q1 | 1.47 | 83.70 | 1,273 | 20.90 | 23.80 | 369 | 359 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Assessment: Opportunities & Risks
Revenue rose to $5,141.2 million in 2025 after $4,241.2 million (2024) and $3,695.6 million (2023) — 39 percent in two years. The first quarter of 2026 added 20.9 percent, to $1,272.7 million. The growth increasingly comes from the younger products: NIKTIMVO climbed year over year to $55.1 million (from $13.6 million) and ZYNYZ to $41.4 million (from $3.1 million).
As of March 31, 2026, $4,015.8 million of cash and marketable securities stood against only $33.8 million of lease liabilities, with the revolving credit facility undrawn. The equity ratio was 76.6 percent and the Altman Z-score 11.94 (data as of July 24, 2026). This company can afford failures — and it takes that option.
JAKAFI, OPZELURA and the JAKAVI royalties all rest on the same molecule, ruxolitinib, and together produced $4,228.7 million, or 82.2 percent of 2025 revenue. The annual report for 2025 states that JAKAFI sales will begin to decline once patent exclusivity expires in 2028; the composition-of-matter patents end in June 2028 and the phosphate patents in December 2028.
The record 2025 net income of $1,286.7 million includes $242.3 million from the Novartis settlement and a $100.0 million upfront payment from Eli Lilly. Without the credit, operating income would have been $1,272.6 million instead of $1,514.9 million. The strong first quarter of 2026 also benefited from an effective tax rate of 11.7 percent, against 32.4 percent a year earlier.
Repurchasing 33,325,849 shares at $60.00 each in June 2024 looks well timed in hindsight. On acquisitions the record is mixed: Escient cost $782.5 million in 2024, of which $679.4 million was expensed immediately — and development of both lead compounds was stopped later that year. Another $1.25 billion went out for Vega Therapeutics on July 6, 2026, again as a one-time research expense.
At roughly $21.3 billion of market capitalization (data as of July 24, 2026), 2025 earnings imply a price-to-earnings ratio of about 17. After deducting net cash of $3,982.0 million, enterprise value equals 11.5 times 2025 operating income — 13.6 times excluding the Novartis credit, and about 14.6 times once the Vega outflow is counted. The mean analyst price target of $111.27 sits roughly 4 percent above the implied share price.
Incyte is not a stock the market overlooked. It is a stock with a date on it. The business works: $5,141.2 million of revenue and $1,286.7 million of net income in 2025, a start to 2026 up 20.9 percent, $4,015.8 million in the bank and effectively no debt. Against that sit 82.2 percent of revenue from a single active ingredient whose U.S. patent protection ends in 2028 by the company's own account, two one-time items inside the record profit, and an acquisition style that charges billion-dollar sums straight to the income statement. Buying here is not a bet on yesterday's numbers but on the pipeline of the day after tomorrow. Not investment advice.
- Incyte reached our research list through our in-house stock scanner: the stock appears on the U.S. side of the "Fundamental Rank (A / A+)" screen, which ranks companies by the quality of their numbers (as of July 26, 2026; 38 U.S. names meet the criteria and the page shows the first 25). On the same date INCY appeared on 19 screens at once, among them Buffett criteria, Terry Smith: Quality, QARP and Peter Lynch: PEG below 1. The screens are recalculated daily.
- Currency of the analysis: it evaluates the annual report 10-K for 2025 (filed February 10, 2026), the quarterly report 10-Q as of March 31, 2026 (filed April 28, 2026) and every filing made since — in particular the 8-K reports dated 08.06., 22.06. and July 6, 2026 and the SC 13D/A ownership filing of May 11, 2026. Two items in the quarterly report are therefore out of date: the CMS rebate dispute was settled on June 22, 2026, and the Vega acquisition closed on July 6, 2026.
- Valuation figures are dated and evergreen: the implied share price of roughly $107 comes from market capitalization of $21.3 billion (data as of July 24, 2026) divided by the 199,782,155 shares the quarterly report reports as of April 21, 2026. Analyses are evergreen; daily prices are not a buy argument.
About the Company
Incyte Corporation ist ein biopharmazeutisches Unternehmen, das in der Entdeckung, Entwicklung und Kommerzialisierung von Therapeutika in den USA, Europa, Kanada und Japan tätig ist. Das Unternehmen bietet JAKAFI zur Behandlung von Myelofibrose (MF), Polycythaemia vera und steroidrefraktärer akuter Graft-versus-Host-Erkrankung an.
| Employees | 2,844 |
|---|---|
| Headquarters | Wilmington, DE |
| Website | incyte.com |
| IPO Date | 4. Nov 1993 |
| Next Earnings | 4. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| William J. Meury | CEO & Director | 1968 |
| Pablo J. Cagnoni M.D., Ph.D. | President and Global Head of R&D | 1963 |
| Thomas Tray | Principal Financial Officer, VP of Finance & Chief Accounting Officer | 1978 |
| Steven H. Stein M.D. | Executive VP, Head of Late-stage Development & Chief Medical Officer | 1967 |
| Mohamed Khairie Issa | Executive Vice President & Head of U.S. Commercial | 1983 |
| Suketu P. Upadhyay | Executive VP & CFO | 1969 |
| Michael James Morrissey | Executive VP & Head of Global Technical Operations | 1964 |
| Alexis Smith | VP & Head of Investor Relations | – |
| Richard A. Hoffman J.D., M.B.A. | Executive VP, General Counsel & Secretary | 1962 |
| Pamela M. Murphy | VP of Investor Relations & Corporate Communications | 1951 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.